Vivesto AB (STO:VIVE)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.2320
-0.0030 (-1.28%)
Jul 11, 2025, 3:35 PM CET
-12.45%
Market Cap 124.83M
Revenue (ttm) n/a
Net Income (ttm) -39.62M
Shares Out 538.04M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,806
Average Volume 329,513
Open 0.2350
Previous Close 0.2350
Day's Range 0.2295 - 0.2350
52-Week Range 0.1992 - 0.3655
Beta 1.08
RSI 51.95
Earnings Date Aug 12, 2025

About Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encaps... [Read more]

Sector Healthcare
Founded 1988
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol VIVE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.